Skip Navigation


Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(6):1000-1006; doi:10.1093/annonc/mdl019
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/6/1000    most recent
mdl019v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schmoll, H. J.
Right arrow Articles by Chan, C. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmoll, H. J.
Right arrow Articles by Chan, C. Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

H. J. Schmoll1,*, M. S. Aapro2, S. Poli-Bigelli3, H.-K. Kim4, K. Park5, K. Jordan1, J. von Pawel6, H. Giezek7, T. Ahmed8 and C. Y. Chan9

1 Martin Luther University Halle/Wittenberg, Halle/Saale, Germany; 2 IMO Clinique de Genolier, Genolier, Switzerland; 3 Instituto de Oncologia Hematologia, Universidad Central de Venezuela, Caracas, Venezuela; 4 Medical Oncology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea; 5 Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 6 Asklepios Fachkliniken, Centre for Pneumology and Thoracic Surgery, Gauting, Germany; 7 Merck Research Laboratories, Brussels, Belgium; 8 Merck Research Laboratories, West Point, Pennsylvania, USA; 9 Merck & Co., Inc., Whitehouse Station, New Jersey, USA

* Correspondence to: Prof. H. J. Schmoll, Martin-Luther-University Halle/Wittenberg, Department of Internal Medicine IV, Ernst-Grube-Str.40, 06120 Halle/Saale, Germany. Tel: +49-345/557-2924; Fax: +49-345/557-2950; E-mail: hans-joachim.schmoll{at}medizin.uni-halle.de

Background: We compared an aprepitant regimen with a control regimen of ondansetron + dexamethasone given for 4 days.

Patients and methods: Patients scheduled to receive cisplatin ≥70 mg/m2 were randomized to either the aprepitant regimen (aprepitant, ondansetron and dexamethasone on day 1; aprepitant and dexamethasone on days 2–3; dexamethasone on day 4) or control regimen (ondansetron + dexamethasone on days 1–4). Patients recorded vomiting, nausea and rescue therapy use. The primary end point was complete response (no vomiting and no use of rescue therapy) in the overall phase (days 1–5 post-cisplatin).

Results: Complete response rates were higher in the aprepitant than control group in the overall (72% versus 61%; P = 0.003), acute (day 1; 88% versus 79%; P = 0.005) and delayed phases (days 2–5; 74% versus 63%; P = 0.004), as were rates of no vomiting (overall 77% versus 62%, P ≤ 0.001; acute 89% versus 81%, P = 0.004; delayed 79% versus 64%, P ≤ 0.001). Rates of no rescue therapy were similar between groups.

Conclusions: Compared with an antiemetic regimen in which ondansetron + dexamethasone were given for 4 days, the aprepitant regimen was superior in the acute, delayed and overall phases of chemotherapy-induced nausea and vomiting. The aprepitant regimen should be considered a new standard of antiemetic therapy for cisplatin-treated patients. www.ClinicalTrials.gov Identifier: NTC00090207

Key words: aprepitant, chemotherapy, cisplatin, dexamethasone, emesis, ondansetron


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
F. Roila, J. Rolski, R. Ramlau, M. Dediu, M. W. Russo, R. R. Bandekar, and S. M. Grunberg
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting
Ann. Onc., November 1, 2009; 20(11): 1867 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
R. J. Gralla and H. Raftopoulos
Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New Studies
J. Oncol. Pract, May 1, 2009; 5(3): 130 - 133.
[Full Text] [PDF]

Home page
 JCOHome page
A. Naeim, S. M. Dy, K. A. Lorenz, H. Sanati, A. Walling, and S. M. Asch
Evidence-Based Recommendations for Cancer Nausea and Vomiting
J. Clin. Oncol., August 10, 2008; 26(23): 3903 - 3910.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. J. Hesketh
Chemotherapy-Induced Nausea and Vomiting
N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494.
[Full Text] [PDF]

Home page
 The OncologistHome page
K. Jordan, C. Sippel, and H.-J. Schmoll
Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations
Oncologist, September 1, 2007; 12(9): 1143 - 1150.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.